The rate of progression of renal disease may not be slower in women compared with men: A patient-level meta-analysis

Tazeen H. Jafar, Christopher H. Schmid, Paul C. Stark, Robert Toto, Giuseppe Remuzzi, Piero Ruggenenti, Carmelita Marcantoni, Gavin Becker, Shahnaz Shahinfar, Paul E. de Jong, Dick de Zeeuw, Anne Lise Kamper, Svend Strangaard, Andrew S. Levey

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

Background. Some studies suggest that progression of renal disease is slower in women than in men. However, other factors that are also associated with progression of renal disease have not always been taken into account. Therefore, we undertook this analysis to explore the independent association of renal disease progression with gender. Methods. We analysed a pooled database of patients with non-diabetic renal disease enrolled in 11 randomized controlled trials evaluating the efficacy of angiotensin-converting enzyme inhibitors (ACEIs) for slowing renal disease progression. The primary end point was the combined outcome of doubling of baseline serum creatinine or onset of end-stage renal disease (ESRD). The secondary end point was the onset of ESRD alone. We performed multivariable Cox proportional hazards analysis to study the independent effect of gender on these end points after adjusting for baseline patient characteristics, and changes from baseline to follow-up systolic blood pressure (SBP) and urine protein (UP) excretion. Results. The total number of patients was 1860: 645 (35%) females and 1215 (65%) males. Mean duration of follow-up was 2.2 years. The proportions randomized to ACEI (51%), mean baseline serum creatinine (2.2 mg/dl) and mean age (52 years) were similar for both genders. Mean baseline SBP was greater in women than in men: 151 vs 147 mmHg (P < 0.001). Mean baseline UP was significantly lower in women compared with men: 1.3 vs 2.1 g/day (P < 0.001). A total of 311 (16.7%) patients developed the primary end point, and 176 (9.5%) developed the secondary end point. The unadjusted relative risk (RR) with 95% confidence interval (CI) for the primary end point in women vs men was 0.98 (0.77-1.24). It became 1.32 (1.03-1.69) after adjusting for the baseline variables and interaction between ACEIs and baseline UP, and 1.36 (1.06-1.75) after adjusting for baseline variables and changes in SBP and UP during follow-up. Similar results were found for the outcome of ESRD. Conclusions. Our findings suggest that the rate of renal disease progression may not be slower, and may even be faster in women compared with men, after adjusting for other factors associated with a faster rate of progression. We caution that most women in our database were of post-menopausal age, and thus our findings may not extend to younger women.

Original languageEnglish (US)
Pages (from-to)2047-2053
Number of pages7
JournalNephrology Dialysis Transplantation
Volume18
Issue number10
DOIs
StatePublished - Oct 1 2003

Fingerprint

Disease Progression
Meta-Analysis
Kidney
Blood Pressure
Angiotensin-Converting Enzyme Inhibitors
Urine
Chronic Kidney Failure
Creatinine
Proteins
Databases
Serum
Randomized Controlled Trials
Confidence Intervals

Keywords

  • Chronic renal disease
  • Gender
  • Renal disease progression

ASJC Scopus subject areas

  • Nephrology
  • Transplantation

Cite this

The rate of progression of renal disease may not be slower in women compared with men : A patient-level meta-analysis. / Jafar, Tazeen H.; Schmid, Christopher H.; Stark, Paul C.; Toto, Robert; Remuzzi, Giuseppe; Ruggenenti, Piero; Marcantoni, Carmelita; Becker, Gavin; Shahinfar, Shahnaz; de Jong, Paul E.; de Zeeuw, Dick; Kamper, Anne Lise; Strangaard, Svend; Levey, Andrew S.

In: Nephrology Dialysis Transplantation, Vol. 18, No. 10, 01.10.2003, p. 2047-2053.

Research output: Contribution to journalArticle

Jafar, TH, Schmid, CH, Stark, PC, Toto, R, Remuzzi, G, Ruggenenti, P, Marcantoni, C, Becker, G, Shahinfar, S, de Jong, PE, de Zeeuw, D, Kamper, AL, Strangaard, S & Levey, AS 2003, 'The rate of progression of renal disease may not be slower in women compared with men: A patient-level meta-analysis', Nephrology Dialysis Transplantation, vol. 18, no. 10, pp. 2047-2053. https://doi.org/10.1093/ndt/gfg317
Jafar, Tazeen H. ; Schmid, Christopher H. ; Stark, Paul C. ; Toto, Robert ; Remuzzi, Giuseppe ; Ruggenenti, Piero ; Marcantoni, Carmelita ; Becker, Gavin ; Shahinfar, Shahnaz ; de Jong, Paul E. ; de Zeeuw, Dick ; Kamper, Anne Lise ; Strangaard, Svend ; Levey, Andrew S. / The rate of progression of renal disease may not be slower in women compared with men : A patient-level meta-analysis. In: Nephrology Dialysis Transplantation. 2003 ; Vol. 18, No. 10. pp. 2047-2053.
@article{d1e36136aa0447b08263a88e1db63abe,
title = "The rate of progression of renal disease may not be slower in women compared with men: A patient-level meta-analysis",
abstract = "Background. Some studies suggest that progression of renal disease is slower in women than in men. However, other factors that are also associated with progression of renal disease have not always been taken into account. Therefore, we undertook this analysis to explore the independent association of renal disease progression with gender. Methods. We analysed a pooled database of patients with non-diabetic renal disease enrolled in 11 randomized controlled trials evaluating the efficacy of angiotensin-converting enzyme inhibitors (ACEIs) for slowing renal disease progression. The primary end point was the combined outcome of doubling of baseline serum creatinine or onset of end-stage renal disease (ESRD). The secondary end point was the onset of ESRD alone. We performed multivariable Cox proportional hazards analysis to study the independent effect of gender on these end points after adjusting for baseline patient characteristics, and changes from baseline to follow-up systolic blood pressure (SBP) and urine protein (UP) excretion. Results. The total number of patients was 1860: 645 (35{\%}) females and 1215 (65{\%}) males. Mean duration of follow-up was 2.2 years. The proportions randomized to ACEI (51{\%}), mean baseline serum creatinine (2.2 mg/dl) and mean age (52 years) were similar for both genders. Mean baseline SBP was greater in women than in men: 151 vs 147 mmHg (P < 0.001). Mean baseline UP was significantly lower in women compared with men: 1.3 vs 2.1 g/day (P < 0.001). A total of 311 (16.7{\%}) patients developed the primary end point, and 176 (9.5{\%}) developed the secondary end point. The unadjusted relative risk (RR) with 95{\%} confidence interval (CI) for the primary end point in women vs men was 0.98 (0.77-1.24). It became 1.32 (1.03-1.69) after adjusting for the baseline variables and interaction between ACEIs and baseline UP, and 1.36 (1.06-1.75) after adjusting for baseline variables and changes in SBP and UP during follow-up. Similar results were found for the outcome of ESRD. Conclusions. Our findings suggest that the rate of renal disease progression may not be slower, and may even be faster in women compared with men, after adjusting for other factors associated with a faster rate of progression. We caution that most women in our database were of post-menopausal age, and thus our findings may not extend to younger women.",
keywords = "Chronic renal disease, Gender, Renal disease progression",
author = "Jafar, {Tazeen H.} and Schmid, {Christopher H.} and Stark, {Paul C.} and Robert Toto and Giuseppe Remuzzi and Piero Ruggenenti and Carmelita Marcantoni and Gavin Becker and Shahnaz Shahinfar and {de Jong}, {Paul E.} and {de Zeeuw}, Dick and Kamper, {Anne Lise} and Svend Strangaard and Levey, {Andrew S.}",
year = "2003",
month = "10",
day = "1",
doi = "10.1093/ndt/gfg317",
language = "English (US)",
volume = "18",
pages = "2047--2053",
journal = "Nephrology Dialysis Transplantation",
issn = "0931-0509",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - The rate of progression of renal disease may not be slower in women compared with men

T2 - A patient-level meta-analysis

AU - Jafar, Tazeen H.

AU - Schmid, Christopher H.

AU - Stark, Paul C.

AU - Toto, Robert

AU - Remuzzi, Giuseppe

AU - Ruggenenti, Piero

AU - Marcantoni, Carmelita

AU - Becker, Gavin

AU - Shahinfar, Shahnaz

AU - de Jong, Paul E.

AU - de Zeeuw, Dick

AU - Kamper, Anne Lise

AU - Strangaard, Svend

AU - Levey, Andrew S.

PY - 2003/10/1

Y1 - 2003/10/1

N2 - Background. Some studies suggest that progression of renal disease is slower in women than in men. However, other factors that are also associated with progression of renal disease have not always been taken into account. Therefore, we undertook this analysis to explore the independent association of renal disease progression with gender. Methods. We analysed a pooled database of patients with non-diabetic renal disease enrolled in 11 randomized controlled trials evaluating the efficacy of angiotensin-converting enzyme inhibitors (ACEIs) for slowing renal disease progression. The primary end point was the combined outcome of doubling of baseline serum creatinine or onset of end-stage renal disease (ESRD). The secondary end point was the onset of ESRD alone. We performed multivariable Cox proportional hazards analysis to study the independent effect of gender on these end points after adjusting for baseline patient characteristics, and changes from baseline to follow-up systolic blood pressure (SBP) and urine protein (UP) excretion. Results. The total number of patients was 1860: 645 (35%) females and 1215 (65%) males. Mean duration of follow-up was 2.2 years. The proportions randomized to ACEI (51%), mean baseline serum creatinine (2.2 mg/dl) and mean age (52 years) were similar for both genders. Mean baseline SBP was greater in women than in men: 151 vs 147 mmHg (P < 0.001). Mean baseline UP was significantly lower in women compared with men: 1.3 vs 2.1 g/day (P < 0.001). A total of 311 (16.7%) patients developed the primary end point, and 176 (9.5%) developed the secondary end point. The unadjusted relative risk (RR) with 95% confidence interval (CI) for the primary end point in women vs men was 0.98 (0.77-1.24). It became 1.32 (1.03-1.69) after adjusting for the baseline variables and interaction between ACEIs and baseline UP, and 1.36 (1.06-1.75) after adjusting for baseline variables and changes in SBP and UP during follow-up. Similar results were found for the outcome of ESRD. Conclusions. Our findings suggest that the rate of renal disease progression may not be slower, and may even be faster in women compared with men, after adjusting for other factors associated with a faster rate of progression. We caution that most women in our database were of post-menopausal age, and thus our findings may not extend to younger women.

AB - Background. Some studies suggest that progression of renal disease is slower in women than in men. However, other factors that are also associated with progression of renal disease have not always been taken into account. Therefore, we undertook this analysis to explore the independent association of renal disease progression with gender. Methods. We analysed a pooled database of patients with non-diabetic renal disease enrolled in 11 randomized controlled trials evaluating the efficacy of angiotensin-converting enzyme inhibitors (ACEIs) for slowing renal disease progression. The primary end point was the combined outcome of doubling of baseline serum creatinine or onset of end-stage renal disease (ESRD). The secondary end point was the onset of ESRD alone. We performed multivariable Cox proportional hazards analysis to study the independent effect of gender on these end points after adjusting for baseline patient characteristics, and changes from baseline to follow-up systolic blood pressure (SBP) and urine protein (UP) excretion. Results. The total number of patients was 1860: 645 (35%) females and 1215 (65%) males. Mean duration of follow-up was 2.2 years. The proportions randomized to ACEI (51%), mean baseline serum creatinine (2.2 mg/dl) and mean age (52 years) were similar for both genders. Mean baseline SBP was greater in women than in men: 151 vs 147 mmHg (P < 0.001). Mean baseline UP was significantly lower in women compared with men: 1.3 vs 2.1 g/day (P < 0.001). A total of 311 (16.7%) patients developed the primary end point, and 176 (9.5%) developed the secondary end point. The unadjusted relative risk (RR) with 95% confidence interval (CI) for the primary end point in women vs men was 0.98 (0.77-1.24). It became 1.32 (1.03-1.69) after adjusting for the baseline variables and interaction between ACEIs and baseline UP, and 1.36 (1.06-1.75) after adjusting for baseline variables and changes in SBP and UP during follow-up. Similar results were found for the outcome of ESRD. Conclusions. Our findings suggest that the rate of renal disease progression may not be slower, and may even be faster in women compared with men, after adjusting for other factors associated with a faster rate of progression. We caution that most women in our database were of post-menopausal age, and thus our findings may not extend to younger women.

KW - Chronic renal disease

KW - Gender

KW - Renal disease progression

UR - http://www.scopus.com/inward/record.url?scp=10744231698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744231698&partnerID=8YFLogxK

U2 - 10.1093/ndt/gfg317

DO - 10.1093/ndt/gfg317

M3 - Article

C2 - 13679479

AN - SCOPUS:10744231698

VL - 18

SP - 2047

EP - 2053

JO - Nephrology Dialysis Transplantation

JF - Nephrology Dialysis Transplantation

SN - 0931-0509

IS - 10

ER -